Voice your opinion on congressional bill S3180-116 and let lawmakers know your stance with UnPac!

Main Subject: Health

Responsibility in Drug Advertising Act of 2020

This bill prohibits direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.

HR2452-116, HR4106-116,

Senate Actions

IntroReferral
Jan. 09 2020	Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Library of Congress Actions

IntroReferral
Jan. 09 2020	Introduced in Senate

Senate bill S3180-116

A bill to amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.

Senate bill S3180-116

A bill to amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.

Promote the cause!

Or use this QR code